Development and acceptability of a decision-aid for food allergy oral immunotherapy in children
- PMID: 39324369
- PMCID: PMC11934854
- DOI: 10.1111/all.16332
Development and acceptability of a decision-aid for food allergy oral immunotherapy in children
Abstract
Background: Limited decision-support tools are available to help shared decision-making (SDM) regarding food oral immunotherapy (OIT) initiation. No current tool covers all foods, forms, and pediatric ages for which OIT is offered.
Methods: In compliance with International Patient Decision Aid Standards criteria, this pediatric decision-aid comparing OIT versus avoidance was developed in three stages. Nested qualitative data assessing OIT decisional needs were supplemented with evidence-synthesis from the OIT literature to create the prototype decision-aid content. This underwent iterative development with food allergy experts and patient advocacy stakeholders until unanimous consensus was reached regarding content, bias, readability, and utility in making a choice. Lastly, the tool underwent validated assessment of decisional acceptability, decisional conflict, and decisional self-efficacy.
Results: The decision-aid underwent 5 iterations, resulting in a 4-page written aid (Flesch-Kincaid reading level 6.1) explaining therapy choices, risks and benefits, providing self-rating for attribute importance for the options and self-assessment regarding how adequate the information was in decision-making. A total of n = 135 caregivers of food-allergic children assessed the decision-aid, noting good acceptability, high decisional self-efficacy (mean score 85.9/100) and low decisional conflict (mean score 20.9/100). Information content was rated adequate and sufficient, the therapy choices wording balanced, and presented without bias for a "best choice." Lower decisional conflict was associated with caregiver-reported anaphylaxis.
Conclusions: This first pediatric OIT decision-aid, agnostic to product, allergen, and age has good acceptability, limited bias, and is associated with low decisional conflict and high decisional self-efficacy. It supports SDM in navigating the decision to start OIT or continue allergen avoidance.
Keywords: allergen avoidance; anaphylaxis; decisional acceptability; decisional conflict; decisional self‐efficacy; decision‐aid; food allergy; oral immunotherapy; shared decision‐making.
© 2024 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Similar articles
-
Development and acceptability of a shared decision-making tool for commercial peanut allergy therapies.Ann Allergy Asthma Immunol. 2020 Jul;125(1):90-96. doi: 10.1016/j.anai.2020.01.030. Epub 2020 Feb 11. Ann Allergy Asthma Immunol. 2020. PMID: 32057932
-
Comparative Effectiveness of a Web-Based Patient Decision Aid for Therapeutic Options for Sickle Cell Disease: Randomized Controlled Trial.J Med Internet Res. 2019 Dec 4;21(12):e14462. doi: 10.2196/14462. J Med Internet Res. 2019. PMID: 31799940 Free PMC article. Clinical Trial.
-
Development of a validated, updated North American pediatric food allergy anaphylaxis management plan.Ann Allergy Asthma Immunol. 2025 Jul;135(1):71-78.e4. doi: 10.1016/j.anai.2025.03.027. Epub 2025 Apr 14. Ann Allergy Asthma Immunol. 2025. PMID: 40239836
-
Oral and Sublingual Immunotherapy for Treatment of IgE-Mediated Food Allergy.Clin Rev Allergy Immunol. 2018 Oct;55(2):139-152. doi: 10.1007/s12016-018-8677-0. Clin Rev Allergy Immunol. 2018. PMID: 29656306 Review.
-
A Review of Shared Decision-Making, Published Protocols, and Post-desensitization Strategies in Oral Immunotherapy (OIT).Curr Allergy Asthma Rep. 2024 Apr;24(4):173-197. doi: 10.1007/s11882-024-01132-2. Epub 2024 Mar 5. Curr Allergy Asthma Rep. 2024. PMID: 38441821 Free PMC article. Review.
Cited by
-
Moving Beyond Desensitization to Tolerance in Food Allergy.J Allergy Clin Immunol Pract. 2025 Apr;13(4):741-744. doi: 10.1016/j.jaip.2025.02.014. Epub 2025 Feb 25. J Allergy Clin Immunol Pract. 2025. PMID: 40010566 Review.
-
Trade-offs from a family perspective: considerations in choosing between omalizumab and complementary alternative medicine for pediatric severe asthma.Front Pharmacol. 2025 Jul 31;16:1621101. doi: 10.3389/fphar.2025.1621101. eCollection 2025. Front Pharmacol. 2025. PMID: 40822491 Free PMC article. Review.
-
Food allergy thresholds, context, and balance in 2025.J Food Allergy. 2024 Aug 1;7(1):27-32. doi: 10.2500/jfa.2025.7.250002. eCollection 2024 Aug. J Food Allergy. 2024. PMID: 40771705 Free PMC article.
-
Addressing Anxiety and Depression in the Allergy Clinic Through Motivational Interviewing, Brief Cognitive Behavioral Therapy, and Curious Questions.J Allergy Clin Immunol Pract. 2025 Aug;13(8):1960-1969.e2. doi: 10.1016/j.jaip.2025.05.020. Epub 2025 May 16. J Allergy Clin Immunol Pract. 2025. PMID: 40383432 Free PMC article. Review.
References
-
- Riggioni C, Oton T, Carmona L, Du Toit G, Skypala I, Santos AF, et al. Immunotherapy and biologics in the management of IgE-mediated food allergy: Systematic review and meta-analyses of efficacy and safety. Allergy 2024. - PubMed
-
- Ebisawa M, Ito K, Fujisawa T, Committee for Japanese Pediatric Guideline for Food Allergy TJSoPA, Clinical I, Japanese Society of A. Japanese guidelines for food allergy 2020. Allergol Int 2020;69:370–86. - PubMed
-
- Pajno GB, Fernandez-Rivas M, Arasi S, Roberts G, Akdis CA, Alvaro-Lozano M, et al. EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy. Allergy 2018;73:799–815. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical